A5066646517- SARS-CoV-2 and COVID-19 Research
- Animal Virus Infections Studies
- COVID-19 Clinical Research Studies
- Viral gastroenteritis research and epidemiology
- COVID-19 Impact on Reproduction
- Respiratory viral infections research
- vaccines and immunoinformatics approaches
- Viral Infections and Immunology Research
- Monoclonal and Polyclonal Antibodies Research
- Bacterial Infections and Vaccines
- Infectious Encephalopathies and Encephalitis
- Long-Term Effects of COVID-19
- Immunotherapy and Immune Responses
- Bacillus and Francisella bacterial research
Beth Israel Deaconess Medical Center
2022-2024
Harvard University
2024
Hadassah Medical Center
2022-2023
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variant BA.2.86 has over 30 mutations in spike compared with BA.2 and XBB.1.5, which raised the possibility that might evade neutralizing antibodies (NAbs) induced by vaccination or infection. In this study, we show NAb titers are substantially lower to but similar slightly higher than other current circulating variants, including EG.5.1, FL.1.5.1. Moreover, against all these variants were vaccinated individuals a history of...
Abstract The SARS-CoV-2 Omicron variant has continued to evolve. XBB is a recombinant between two BA.2 sublineages, XBB.1 includes the G252V mutation, and XBB.1.5 F486P mutations. rapidly increased in frequency become dominant virus New England. bivalent mRNA vaccine boosters have been shown increase neutralizing antibody (NAb) titers multiple variants, but durability of these responses remains be determined. We assessed humoral cellular immune 30 participants who received performed assays...
Abstract A limitation of current SARS-CoV-2 vaccines is that they provide minimal protection against infection with Omicron subvariants 1,2 , although still severe disease. Enhanced mucosal immunity may be required to block and onward transmission. Intranasal administration has proven inconsistent 3–7 suggesting alternative immunization strategies required. Here we show intratracheal boosting a bivalent Ad26-based vaccine results in substantial induction humoral cellular near-complete BQ.1.1...
ABSTRACT The continued evolution of SARS-CoV-2 may lead to evasion vaccine immunity and natural immunity. A highly mutated Omicron variant BA.2.86 has recently been identified with over 30 amino acid changes in Spike compared BA.2 XBB.1.5. As September 4, 2023, 37 sequences from 10 countries, which is likely an underestimate due limited surveillance. ability evade NAbs other currently circulating variants remains unknown. Our data show that NAb responses were lower than but comparable or...
Messenger RNA (mRNA) vaccines were highly effective against the ancestral SARS-CoV-2 strain, but efficacy of bivalent mRNA boosters XBB variants was substantially lower. Here, we show limited durability neutralizing antibody (NAb) responses and isotype switching to immunoglobulin G4 (IgG4) following boosting. Bivalent boosting elicited modest XBB.1-, XBB.1.5-, XBB.1.16-specific NAbs that waned rapidly within 3 months. In contrast, induced more robust sustained WA1/2020 suggesting immune...
Current COVID-19 vaccines provide robust protection against severe disease but minimal acquisition of infection. Intramuscularly administered induce serum neutralizing antibodies (NAbs), their ability to boost mucosal immune responses remains be determined. In this study, we show that the XBB.1.5 messenger RNA (mRNA) boosters result in increased neutralization multiple acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants humans, including dominant circulating variant JN.1....
Waning immunity following mRNA vaccination and the emergence of SARS-CoV-2 variants has led to reduced vaccine efficacy against both symptomatic infection severe disease. Bivalent boosters expressing Omicron BA.5 ancestral WA1/2020 Spike proteins have been developed approved, because is currently dominant variant substantially evades neutralizing antibodies (NAbs). Our data show that NAb titers were comparable monovalent bivalent boosters.
ABSTRACT Omicron BA.5 has been the globally dominant SARS-CoV-2 variant and demonstrated substantial neutralization escape compared with prior variants. Additional variants have recently emerged, including BA.4.6, BF.7, BA.2.75.2, BQ.1.1, all of which Spike R346T mutation. In particular, BQ.1.1 rapidly increased in frequency, declined to less than half viruses United States. Our data demonstrate that BA.2.75.2 NAbs induced by infection vaccination more effectively BA.5. NAb titers were lower...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines demonstrate reduced protection against acquisition of BA.5 subvariant but are still effective severe disease. However, immune correlates remain unknown. We report the immunogenicity and protective efficacy vaccine regimens consisting vector-based Ad26.COV2.S adjuvanted spike ferritin nanoparticle (SpFN) a high-dose, mismatched Omicron challenge in macaques. The SpFNx3 Ad26 + SpFNx2 elicit higher antibody responses than...
The viral vector-based COVID-19 vaccine Ad26.COV2.S has been recommended by the WHO since 2021 and administered to over 200 million people. Prior studies have shown that induces durable neutralizing antibodies (NAbs) increase in coverage of variants time, even absence boosting or infection. Here, we studied humoral responses following vaccination individuals enrolled initial Phase 1/2a trial 2020. Through 8 months post vaccination, serum NAb increased variants, including B.1.351 (Beta)...
We report the direct comparison of monomeric, dimeric and trimeric RBD protein subunit vaccines to a virus-like particle (VLP) displaying RBD. After two three doses, dimer trimer elicited antibody levels in mice comparable an RBD-VLP. Furthermore, Omicron (BA.1) hetero-dimer induced neutralizing activity similar A RBD-VLP also shows breadth other SARS-CoV-2 variants-of-concern (VOCs).